No Data
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95
JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)